EAU 2013 - Programme Book - YouMed

Monday
Monday, 18 March - EAU Programme
314 Programme Book
Abstract Session
15.45 - 17.15 Medical treatment of RCC
Yellow Hall 1-2-3 - Level N1
Poster Session 90
Chairs: G. Kramer, Vienna (AT)
H. Uemura, Osaka (JP)
Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes
in length, followed by 2 minutes for discussion. Extended presentations (*) are 4 minutes in length, followed
by 2 minutes for discussion.
1097 Prognostic factors for patients with metastatic renal cell carcinoma in the era of targeted therapy
D. You, I.G. Jeong, S. Park, J.Y. Joung, J.H. Hong, H. Ahn, C-S. Kim (Seoul, Ulsan, South Korea; New
Brunswick, United States of America)
1098 Tumor growth rate should be applied in the definition of progression disease during molecular targeted
therapy in patients with metastatic renal cell carcinoma
H.L. Zhang, D.W. Ye, G.H. Shi (Shanghai, China)
1099 Individualization of medical treatment in metastasized renal cell carcinoma by measuring the plasma levels
of sunitinib, sorafenib and pazopanib – first clinical experiences
C. Keil, A. Nockher, L. Götze, P. Olbert, R. Hofmann, A. Hegele (Marburg, Germany)
1100 Association of pharmacokinetics of sunitinib with treatment outcome and adverse events in advanced
renal cell carcinoma patients
N. Tsuchiya, N. Fujiyama, S. Narita, T. Inoue, K. Numakura, S. Akihama, M. Saito, S. Satoh, M. Miura,
T. Habuchi (Akita, Japan)
1101 Identification of a potential molecular marker of response to high-dose interleukin-2 in metastatic renal
cell carcinoma patients
C.D. Jacobs, G. Lipowska-Bhalla, N. Dalal, F. Thistlethwaite, R.E. Hawkins, D.G. Rothwell (Manchester,
United Kingdom)
1102 Body-mass-index and survival of patients with metastastic renal cell carcinoma: Data from the German
prospective RCC Registry
P.J. Goebell, L. Müller, U. Von Verschuer, H.J. Hurtz, M. Franzem, M. Vogt, N. Marschner (Erlangen, Leer,
Essen, Halle (Saale), Freiburg, Germany)
1103 FDG PET/CT as imaging biomarker for advanced renal cell carcinoma
N. Nakaigawa, M. Yao, N. Hayashi, U. Tateishi, T. Inoue, Y. Kubota (Yokohama, Japan)
1104 Frequency and risk factors of sorafenib-induced high-grade skin rash in Japanese patients with advanced
renal cell carcinoma
N. Tsuchiya, S. Narita, T. Inoue, N. Hasunuma, K. Numakura, M. Saito, S. Satoh, T. Notoya, N. Fujishima,
S. Hatakeyama, C. Ohyama, T. Habuchi (Akita, Japan)
1105 Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava
thrombectomy. A French retrospective study of 13 cases
P. Bigot, J.C. Bernhard, E. Xylinas, T. Fardoun, J. Berger, M. Rouprêt, S. Lagabrielle, S. Lebdai, M. Ammi,
H. Baumert, K. Bensalah, B. Escudier, N. Grenier, J.F. Hetet, J.A. Long, P. Paparel, N. Rioux-Leclercq,
A-R. Azzouzi, M. Soulié, J-J. Patard (Angers, Bordeaux, Paris, Rennes, Limoges, Villejuif, Nantes, Grenoble,
Lyon, Toulouse, Le Kremlin-Bicêtre, France)